Status:
UNKNOWN
Gastroesophageal Varices in Cavernoma
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Gastroesophageal Varices
Myeloproliferative Neoplasm
Eligibility:
All Genders
18-75 years
Brief Summary
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortal...
Eligibility Criteria
Inclusion
- male or female patients aged 18-75
- diagnosed as portal hypertension and portal cavernoma by contrast-enhanced computed tomography
- underwent JAK2 mutation test
Exclusion
- combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.
- other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04525768
Start Date
October 1 2020
End Date
September 30 2022
Last Update
August 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, Shanghai Municipality, China, 200032